426 related articles for article (PubMed ID: 32428864)
1. Angiotensin converting enzyme-2 as therapeutic target in COVID-19.
Roshanravan N; Ghaffari S; Hedayati M
Diabetes Metab Syndr; 2020; 14(4):637-639. PubMed ID: 32428864
[TBL] [Abstract][Full Text] [Related]
2. Organ-protective effect of angiotensin-converting enzyme 2 and its effect on the prognosis of COVID-19.
Cheng H; Wang Y; Wang GQ
J Med Virol; 2020 Jul; 92(7):726-730. PubMed ID: 32221983
[TBL] [Abstract][Full Text] [Related]
3. A brief review of interplay between vitamin D and angiotensin-converting enzyme 2: Implications for a potential treatment for COVID-19.
Malek Mahdavi A
Rev Med Virol; 2020 Sep; 30(5):e2119. PubMed ID: 32584474
[TBL] [Abstract][Full Text] [Related]
4. ACE2, the kidney and the emergence of COVID-19 two decades after ACE2 discovery.
Lores E; Wysocki J; Batlle D
Clin Sci (Lond); 2020 Nov; 134(21):2791-2805. PubMed ID: 33135725
[TBL] [Abstract][Full Text] [Related]
5. Expressions and significances of the angiotensin-converting enzyme 2 gene, the receptor of SARS-CoV-2 for COVID-19.
Fu J; Zhou B; Zhang L; Balaji KS; Wei C; Liu X; Chen H; Peng J; Fu J
Mol Biol Rep; 2020 Jun; 47(6):4383-4392. PubMed ID: 32410141
[TBL] [Abstract][Full Text] [Related]
6. ACE2 and ACE: structure-based insights into mechanism, regulation and receptor recognition by SARS-CoV.
Lubbe L; Cozier GE; Oosthuizen D; Acharya KR; Sturrock ED
Clin Sci (Lond); 2020 Nov; 134(21):2851-2871. PubMed ID: 33146371
[TBL] [Abstract][Full Text] [Related]
7. Scaffold morphing of arbidol (umifenovir) in search of multi-targeting therapy halting the interaction of SARS-CoV-2 with ACE2 and other proteases involved in COVID-19.
Choudhary S; Silakari O
Virus Res; 2020 Nov; 289():198146. PubMed ID: 32866534
[TBL] [Abstract][Full Text] [Related]
8. Natural Flavonoids as Potential Angiotensin-Converting Enzyme 2 Inhibitors for Anti-SARS-CoV-2.
Muchtaridi M; Fauzi M; Khairul Ikram NK; Mohd Gazzali A; Wahab HA
Molecules; 2020 Sep; 25(17):. PubMed ID: 32882868
[TBL] [Abstract][Full Text] [Related]
9. JAK Inhibition as a New Treatment Strategy for Patients with COVID-19.
Seif F; Aazami H; Khoshmirsafa M; Kamali M; Mohsenzadegan M; Pornour M; Mansouri D
Int Arch Allergy Immunol; 2020; 181(6):467-475. PubMed ID: 32392562
[TBL] [Abstract][Full Text] [Related]
10. Endocrine aspects of ACE2 regulation: RAAS, steroid hormones and SARS-CoV-2.
Young MJ; Clyne CD; Chapman KE
J Endocrinol; 2020 Nov; 247(2):R45-R62. PubMed ID: 32966970
[TBL] [Abstract][Full Text] [Related]
11. Coronavirus disease 2019 (COVID-19) and the renin-angiotensin system: A closer look at angiotensin-converting enzyme 2 (ACE2).
Zemlin AE; Wiese OJ
Ann Clin Biochem; 2020 Sep; 57(5):339-350. PubMed ID: 32369402
[TBL] [Abstract][Full Text] [Related]
12. Inhibition of SARS-CoV-2 Infections in Engineered Human Tissues Using Clinical-Grade Soluble Human ACE2.
Monteil V; Kwon H; Prado P; Hagelkrüys A; Wimmer RA; Stahl M; Leopoldi A; Garreta E; Hurtado Del Pozo C; Prosper F; Romero JP; Wirnsberger G; Zhang H; Slutsky AS; Conder R; Montserrat N; Mirazimi A; Penninger JM
Cell; 2020 May; 181(4):905-913.e7. PubMed ID: 32333836
[TBL] [Abstract][Full Text] [Related]
13. Identification of SARS-CoV-2 Cell Entry Inhibitors by Drug Repurposing Using
Choudhary S; Malik YS; Tomar S
Front Immunol; 2020; 11():1664. PubMed ID: 32754161
[TBL] [Abstract][Full Text] [Related]
14. Coevolution, Dynamics and Allostery Conspire in Shaping Cooperative Binding and Signal Transmission of the SARS-CoV-2 Spike Protein with Human Angiotensin-Converting Enzyme 2.
Verkhivker G
Int J Mol Sci; 2020 Nov; 21(21):. PubMed ID: 33158276
[TBL] [Abstract][Full Text] [Related]
15. The mechanistic overview of SARS-CoV-2 using angiotensin-converting enzyme 2 to enter the cell for replication: possible treatment options related to the renin-angiotensin system.
Offringa A; Montijn R; Singh S; Paul M; Pinto YM; Pinto-Sietsma SJ
Eur Heart J Cardiovasc Pharmacother; 2020 Sep; 6(5):317-325. PubMed ID: 32464637
[TBL] [Abstract][Full Text] [Related]
16. Angiotensin II suppression in SARS-CoV-2 infection: a therapeutic approach.
Lamas-Barreiro JM; Alonso-Suárez M; Fernández-Martín JJ; Saavedra-Alonso JA
Nefrologia (Engl Ed); 2020; 40(3):213-216. PubMed ID: 32456945
[No Abstract] [Full Text] [Related]
17. Role of angiotensin-converting enzyme 2 and pericytes in cardiac complications of COVID-19 infection.
Robinson FA; Mihealsick RP; Wagener BM; Hanna P; Poston MD; Efimov IR; Shivkumar K; Hoover DB
Am J Physiol Heart Circ Physiol; 2020 Nov; 319(5):H1059-H1068. PubMed ID: 33036546
[TBL] [Abstract][Full Text] [Related]
18. A mouse-adapted model of SARS-CoV-2 to test COVID-19 countermeasures.
Dinnon KH; Leist SR; Schäfer A; Edwards CE; Martinez DR; Montgomery SA; West A; Yount BL; Hou YJ; Adams LE; Gully KL; Brown AJ; Huang E; Bryant MD; Choong IC; Glenn JS; Gralinski LE; Sheahan TP; Baric RS
Nature; 2020 Oct; 586(7830):560-566. PubMed ID: 32854108
[TBL] [Abstract][Full Text] [Related]
19. COVID-19 and Cardiovascular Disease.
Clerkin KJ; Fried JA; Raikhelkar J; Sayer G; Griffin JM; Masoumi A; Jain SS; Burkhoff D; Kumaraiah D; Rabbani L; Schwartz A; Uriel N
Circulation; 2020 May; 141(20):1648-1655. PubMed ID: 32200663
[TBL] [Abstract][Full Text] [Related]
20. The pivotal link between ACE2 deficiency and SARS-CoV-2 infection.
Verdecchia P; Cavallini C; Spanevello A; Angeli F
Eur J Intern Med; 2020 Jun; 76():14-20. PubMed ID: 32336612
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
